Search
GnRH pharmaccine
go.drugbank.com/drugs/DB05815ExperimentalThe GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle". … The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation
CHGN111
go.drugbank.com/drugs/DB06376ExperimentalNumerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.
(-)-menthol 1-propylene glycol carbonate
go.drugbank.com/drugs/DB14136InvestigationalMixtures: Thera Derm Roll OnINNO-305
go.drugbank.com/drugs/DB06025InvestigationalINNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission. … The vaccine is a polyvalent Wilms tumor gene 1 (WT1) peptide analog vaccine.
Ruplizumab
go.drugbank.com/drugs/DB06475InvestigationalRuplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.
Guanoxan
go.drugbank.com/drugs/DB13211ApprovedGuanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. … Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.
Clobutinol
go.drugbank.com/drugs/DB09004ApprovedWithdrawnClobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.
Metenkefalin
go.drugbank.com/drugs/DB12668InvestigationalMetenkefalin is an endogenous opioid and beta-endorphin.[A203225] It has been shown to reduce chromosomal abberations in patients with multiple sclerosis. … [A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]
Methyl salicylate 2-ethylbutyrate
go.drugbank.com/drugs/DB14130InvestigationalMixtures: Thera Derm Roll OnCYT007-TNFQb
go.drugbank.com/drugs/DB05758ExperimentalCYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis. … The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.